Vera Therapeutics closed at $31.97 on Nov 4, up 4.10%, 42.6% below its 52-week closing high. Volume of 2.0M shares was 1.20× its 20-day average (close to normal).
Split-adjusted performance: +8.7% over one month, -12.6% over six months, +23.2% over one year.
Short interest was 13.6M shares at the Oct 15 settlement, down 21.2% from the prior report (21.5% of float, 7.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| VERAVera Therapeutics | $31.97 | +4.10% | −12.6% | — | — | — | $2.30B | |
| IMNMImmunome | $19.52 | −3.89% | −16.1% | −100.0% | — | — | $2.30B | Compare |
| BHVNBiohaven | $15.24 | −2.37% | +51.8% | — | — | — | $2.30B | Compare |
| AUPHAurinia Pharmaceuticals | $17.11 | +3.32% | +5.3% | +13.9% | 37.9% | 7.3 | $2.29B | Compare |
| PVLAPalvella Therapeutics | $162.28 | +6.11% | +24.7% | — | — | — | $2.34B | Compare |
| SEPNSepterna | $47.88 | +9.57% | +93.8% | +22375.6% | −48.7% | — | $2.23B | Compare |
| TRLVTrulieve Cannabis | $11.60 | +0.52% | — | — | −149.8% | — | $2.23B | Compare |
| ZYMEZymeworks | $30.94 | +2.69% | +12.1% | −90.6% | −980.8% | — | $2.22B | Compare |
| PRGOPERRIGO | $15.83 | +0.83% | +29.1% | −3.2% | 7.3% | — | $2.20B | Compare |
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
